Cardiff Oncology (CRDF) Stock: Buy, Sell, or Hold?
CRDF - Cardiff Oncology, Inc. Common Stock
$1.24
-0.04 (-3.13%)
âŧ
5d:
-9.49%
30d:
+26.0%
90d:
-0.8%
WAIT
LOW Confidence
Analysis Updated: Sep 25, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When CRDF Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CRDF is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CRDF is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CRDF is currently trading at $1.24, which is considered slightly high relative to its 30-day fair value range of $0.95 to $1.29.
Technical Outlook: Technically, CRDF is in a strong downtrend. The price is currently testing key support at $1.22. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: CRDF scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.81 (+368.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CRDF is in a strong downtrend. The price is currently testing key support at $1.22. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: CRDF scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.81 (+368.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$0.95 -
$1.29
Company Quality Score
27/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
36.8%
All Signals
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.1%)
- BULLISH: Trading 368.9% below Wall St target ($5.81)
- WARNING: Composite score 27/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.95 -
$1.29
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.22
Resistance Level
$1.51
Current Trend
Strong Downtrend
Technical data as of
Sep 25, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.32
Wall Street Target
$5.81
(+368.9%)
Revenue Growth (YoY)
-14.1%
Share & Embed Analysis
Last updated: September 27, 2026 1:09 AM ET
Data refreshes hourly during market hours. Next update: 2:09 AM
Data refreshes hourly during market hours. Next update: 2:09 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRDF showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 49 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1181 | 61 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$48 | 57 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 40 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$118 | 66 BUY |
